Research Advances in Sarcopenia

doi:10.3969/j.issn.2095-1396.2020.01.010

Abstract

Abstract:

Sarcopenia is an age-related，progressive syndrome，which is characterized by decline of skeletal muscle mass，strength and muscle function. It has high morbidity and complex pathogenesis. Then it leads to the loss of life ability and the decline in life quality of the aged. It is significant to diagnose，prevent and treat sarcopenia early in clinic and practice. In this review，etiology and pathological mechanism of sarcopenia，present treatment and models of the disease are summarized systematically，which could provide a reference for exploring its machenism deeply and screening drugs of the prevention and treatment of sarcopenia.

Key words: sarcopenia, pathogenesis, treatment, model of disease, aging

Cite this article

HE Pan, LIU Yue-tao, DU Guan-hua, QIN Xue-mei. Research Advances in Sarcopenia[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 47-53.

share this article

0
/ Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2020.01.010

http://actanp.hebeinu.edu.cn/EN/Y2020/V10/I1/47

References

[1] 杜艳萍, 朱汉民. 肌少症的诊疗和防治研究[J]. 中华骨质疏松和骨矿盐疾病杂志, 2014, 7(1): 1-8.

[2] Stefan D Anker, John E Morley, Stephan von Haehling. Welcome to the ICD-10 code for sarcopenia[J]. J Cachexia, Sarcopenia and Muscle, 2016, 7(5): 512-514.

[3] 于宝海, 吴文娟. 2018 欧洲肌少症共识解读[J]. 河北医科大学学报, 2019, 40(4): 373-379, 384.

[4] 李亚奥, 修双玲, 王立. 中老年男性2型糖尿病患者肌少症与骨密度的相关性研究[J]. 首都医科大学学报, 2020, 41(1): 119-124.

[5] Tournadre A, Vial G, Capel F, et al. Sarcopenia[J]. Joint Bone Spine, 2019, 86(3): 309-314.

[6] 严淑, 陆亚华, 汪良芝. 老年肌少症的诊治和研究新进展[J]. 中国老年学杂志, 2018, 38 (22): 5610-5613.

[7] Young Nam Kwon, Sung-Sang Yoon. Sarcopenia: neurological point of view[J]. J Bone Metabolism, 2017, 24(2): 83-89.

[8] Drey M, Grösch C, Neuwirth C, et al. The motor unit number index (MUNIX) in sarcopenic patients[J]. Experimental Gerontology, 2013, 48(4): 381-384.

[9] Mikael Altun, Henrike C Besche, Herman Overkleeft, et al. Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway[J]. J Biological Chemistry, 2010, 285(51): 39597-39608.

[10] 王今越, 王小虹, 冯维斗. IRS1, Akt, FOXO1在少肌症发生及其运动性缓解中的作用[J]. 成都体育学院学报, 2012, 38(7): 86-91.

[11] Sebastiaan Dalle, Lenka Rossmeislova, Katrien Koppo. The role of inflammation in age-related sarcopenia[J]. Frontiers in Physiology, 2017, 8: 1045.

[12] Laura A Schaap, Saskia M F Pluijm, Dorly J H Deeg, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength[J]. J Gerontology Series A: Biomedical Sciences and Medical Sciences, 2009, 64(11): 1183-1189.

[13] 王今越, 王小虹, 冯维斗. p38, NF-κB, IL-6在少肌症发生及其运动性缓解中的作用[J]. 山东体育学院学报, 2012, 28(4): 51-56.

[14] 林白阳. 老年 COPD 患者血清 IL-6, IL-10水平与肌少症的关系[D]. 太原：山西医科大学, 2019.

[15] Aphrodite Vasilaki, Malcolm J Jackson. Role of reactive oxygen species in the defective regeneration seen in aging muscle[J]. Free Radical Biology and Medicine, 2013, 65: 317-323.

[16] Adam P W Johnston, Michael De Lisio, Gianni Parise. Resistance training, sarcopenia, and the mitochondrial theory of aging[J]. Applied Physiology, Nutrition, and Metabolism, 2007, 33(1): 191-199.

[17] Ramy K A Sayed, Marisol Fernández-Ortiz, Maria E Diaz-Casado, et al. Lack of NLRP3 inflammasome activation reduces age-dependent sarcopenia and mitochondrial dysfunction, favoring the prophylactic effect of melatonin[J]. J Gerontology: Series A, 2019, 74(11): 1699-1708.

[18] 梁计陵, 谢金凤, 王岑依, 等. 运动诱导细胞自噬在老年肌少症康复中的研究进展[J]. 中国康复理论与实践, 2019, 25(3): 334-337.

[19] Tomonori Sato, Yoshiaki Ito, Takashi Nagasawa. L-Lysine suppresses myofibrillar protein degradation and autophagy in skeletal muscles of senescence-accelerated mouse prone 8[J]. Biogerontology, 2017, 18(1): 85-95.

[20] Richie Barclay, Nicholas A Burd, Christopher Tyler, et al. The role of the IGF-1 signalling cascade in muscle protein synthesis and anabolic resistance in ageing skeletal muscle[J]. Frontiers in Nutrition, 2019, 6: 146.

[21] Silvia Giovannini, Emanuele Marzetti, Stephen E Borst, et al. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults [J]. Mechanisms of Ageing and Development, 2008, 129(10): 593-601.

[22] Mee-Sup Yoon. mTOR as a key regulator in maintaining skeletal muscle mass[J]. Frontiers in Physiology, 2017, 8:788.

[23] Olivier Le Bacquer, Kristell Combe, Veronique Patrac, et al. 4E-BP1 and 4E-BP2 double knockout mice are protected from aging-associated sarcopenia[J]. J Cachexia, Sarcopenia and Muscle, 2019, 10, 696-709.

[24] 金晶, 冯祎中, 黄伟, 等. 运动通过激活卫星细胞功能延缓和改善骨骼肌衰减症的研究进展[J]. 体育科学, 2019, 39(8): 73-80.

[25] 卜凡. 耐力运动经AMPK介导的自噬维持老年小鼠骨骼肌卫星细胞干细胞属性[D]. 重庆: 重庆医科大学, 2019.

[26] Parag Kundu, Eran Blacher, Eran Elinav, et al. Our gut microbiome: the evolving inner self[J]. Cell, 2017, 171(7): 1481-1493.

[27] Martina Casati, Evelyn Ferri, Domenico Azzolino, et al. Gut microbiota and physical frailty through the mediation of sarcopenia[J]. Experimental Gerontology, 2019, 124: 110639.

[28] Melouane, Aicha Ghanemi, Abdelaziz Yoshioka, et al. Functional genomics applications and therapeutic implications in sarcopenia[J]. Mutation Research/Reviews in Mutation Research, 2019, 781, 175-185.

[29] Iryna Rusanova, Jose Fernandez-Martinez, Marisol Fernandez-Ortiz, et al. Involvement of plasma miRNAs, muscle miRNAs and mitochondrial miRNAs in the pathophysiology of frailty[J]. Experimental Gerontology, 2019, 124: 110637.

[30] Darren G Candow, Scott C Forbes, Phillip D Chilibeck, et al. Variables influencing the effectiveness of creatine supplementation as a therapeutic intervention for sarcopenia[J]. Frontiers in Nutrition, 2019, 6: 124.

[31] Francisco Martinez-Arnau, Fonfria-Vivas, Omar Cauli. Beneficial effects of leucine supplementation on criteria for sarcopenia: a systematic review[J]. Nutrients, 2019, 11(10): 2504.

[32] Mareike S Pötsch, Anika Tschirner, Sandra Palus, et al. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats[J]. J Cachexia, Sarcopenia and Muscle, 2014, 5(2): 149-158.

[33] Peter J Snyder, Helen Peachey, Peter Hannoush, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age[J]. J Clinical Endocrinology & Metabolism, 1999, 84(8): 2647-2653.

[34] Deepa Sumukadas, Miles Witham, Allan D Struthers, et al. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial[J]. Cmaj, 2007, 177(8): 867-874.

[35] 魏静, 魏凯善, 罗敏, 等. 从“脾”论治肌肉减少症[J]. 中医药临床杂志, 2019, 31 (7): 1282-1284.

[36] 毛智慧, 刘晓亭, 张欢, 等. 健运脾胃法干预老年肌肉衰减综合征之机理探讨[J]. 辽宁中医杂志, 2017, 44(8): 1631-1634.

[37] 梁清月, 王仲, 刘戎, 等. 加减八珍汤联合营养支持治疗老年骨骼肌减少症疗效观察[J]. 中国中西医结合杂志, 2019, 39(7): 821-825.

[38] 温春瑜, 陈颖颖, 彭鹏, 等. 补中益气汤加减辅助治疗老年肌少症的临床疗效观察[J]. 实用中西医结合临床, 2018, 18(7): 72-73.

[39] 任璇璇, 姚惠, 汪涛. 八珍汤联合基础干预治疗老年肌少症临床疗效观察[J]. 中国现代医生, 2016, 54(16): 127-130.

[40] 徐划萍, 金国琴, 龚张斌, 等. 补肾益气方药延缓骨骼肌衰老的实验研究[J]. 中国临床药理学杂志, 2015, 31(1): 63-66.

[41] 王新梅. 天麻多糖延缓D-半乳糖诱导小鼠骨骼肌衰老的实验研究[D]. 遵义：遵义医科大学, 2019.

[42] 李郡, 汪双双, 杨晓军, 等. 从86例处方浅谈邓铁涛教授治疗脾胃肌肉疾病用药规律特点[J]. 时珍国医国药, 2015, 26(7): 1742-1743.

[43] 鲁飞翔. 肌肉衰减综合征小鼠模型的建立及相关分子和功能的评价[D]. 锦州：锦州医科大学, 2017.

[44] 王丛丛. 尿石素 B 对地塞米松诱导的肌肉衰减综合征小鼠模型的影响[D]. 锦州：锦州医科大学, 2018.

[45] 王月兵. 抗阻力运动结合肌酸补充对肌肉衰减综合征模型小鼠的影响[D]. 锦州：锦州医科大学, 2017.

[46] 王全全. 人脐带华通氏胶间充质干细胞治疗肌肉衰减综合征的实验研究[D]. 济南: 山东大学, 2018.

[47] 连雯雯, 刘艾林, 杜冠华. DL0410改善D-半乳糖致衰老小鼠认知功能的线粒体保护机制研究[J]. 神经药理学报, 2017, 7(02): 60.

[48] 王雪飞, 康金森. 香茅精油对D-半乳糖联合三氯化铝致老年痴呆小鼠的保护作用[J]. 神经药理学报, 2017, 7(02): 38-39.

[49] 王婧. D-半乳糖对肌肉衰减综合征的诱导效应和抗肌肉衰减因子研究[D]. 北京：中国疾病预防控制中心, 2019.

[50] Mohammed Mukhram Azeemuddin, Chamallamudi Mallikarjuna Rao, Mohamed Rafiq, et al. Pharmacological investigation of ‘HIM-CHX’: A herbal combination in the experimental muscle wasting condition[J]. Experimental Gerontology, 2019, 125: 110663.

[51] Meador B M, Mirza K A, Tian M, et al. The green tea polyphenol Epigallocatechin-3-Gallate (EGCg) attenuates skeletal muscle atrophy in a rat model of sarcopenia[J]. The J Frailty & Aging, 2015, 4(4): 209-215.

[52] Deepa Sathyaseelan, Holly Van Remmen, Susan V Brooks, et al. Accelerated sarcopenia in Cu/Zn superoxide dismutase knockout mice[J]. Free Radical Biology and Medicine, 2019, 132: 19-23.

Related Articles 15

[1]	LEI Luo-chun, AI Ying, YANG Jun-ying, ZHENG Wei. Effect of Routine and Optimized Treatment in ICU on Cerebral Resuscitation in Patients with Post-Cardiac Arrest Syndrome#br# [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 1-4.
[2]	ZHANG Li-huan, CHU Bao, ZHANG Xiao-yan, SUN Ying-ru, GONG Chun-dong, WANG He-bo. Research Progress of Magnesium in Pathogenesis and Treatment of Migraine [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 29-33.
[3]	XING Yuan，ZHANG Nan，ZHANG Wei，REN Lei-ming. Neurotoxicity and Prevention of Local Anesthetics in Central Nervous System [J]. Acta Neuropharmacologica, 2018, 8(3): 15-.
[4]	DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua. New Strategies for the Drug Development of Anti-cerebral Ischemia —Advances in the Etiology and Drug Development of Acute Cerebral Ischemia [J]. Acta Neuropharmacologica, 2018, 8(1): 1-8.
[5]	LIU Nuo，WANG Zhen-zhen，CHEN Nai-hong. The Role of Gut Flora in the Pathogenesis of Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2017, 7(5): 28-.
[6]	GAO Zhi-hong1，ZUO Ya-qi2，ZHANG Xiao-li1. A New Idea of Astragaloside-Induced Bone Marrow Mesenchymal Stem Cells in the Treatment of Parkinson’s Disease [J]. Acta Neuropharmacologica, 2017, 7(5): 39-44.
[7]	GAO Jin-chao， ZHAO Wen-juan， YIN Ming. Progress in the Relationship of Apolipoprotein E4 on Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2016, 6(6): 31-39.
[8]	LUO Lin-ming, JI Yi-na, CHEN Nai-hong. Research Progress on the Effect of Neural Stem Cells in the Occurrence and Development of Glioma [J]. Acta Neuropharmacologica, 2015, 5(5): 28-33.
[9]	XUE Zhan-xia，GAO Yong-shan. Research Progress of Postoperative Delirium [J]. Acta Neuropharmacologica, 2014, 4(4): 20-27.
[10]	WU Zhi-gang，SHEN Li-xia. Treatment for Lower Urinary Tract Dysfunction in Patients with Parkinson’s Disease [J]. Acta Neuropharmacologica, 2014, 4(4): 36-41.
[11]	LIU Feng-xi, NIU Kai, XUE Gui-ping. The Therapeutic Progress of Vascular Dementia in Terms of Modern Medicine and Chinese Traditional Treatment [J]. Acta Neuropharmacologica, 2014, 4(1): 29-33.
[12]	WANG Zhen-zhen, CHEN Nai-hong. Depression and Inflammation [J]. Acta Neuropharmacologica, 2013, 3(5): 27-37.
[13]	LIU Hong-bin，WU Hai-xia. Overview of the Pathogenesis and Animal Models of Alzheimer's Disease [J]. Acta Neuropharmacologica, 2013, 3(4): 14-22.
[14]	LIU Zhi-jun. Epidemiology and Pharmacotherapy of Adult Attention Deficit/Hyperactivity Disorde: Current Status [J]. Acta Neuropharmacologica, 2012, 2(5): 31-39.
[15]	JIN Miao, AN Hong-mei. Animal Models of Alzheimer’s Disease and Pharmacotherapeutics [J]. Acta Neuropharmacologica, 2011, 1(6): 28-36.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP